Nancy Phelan

Eved is your global payment partner for Events, Media, and Entertainment. We automate and centralize the processing of invoices and payments with a single workflow: providing security, efficiency, and visibility. Over the last 5 years, Eved has delighted the most sophisticated global companies in the Fortune 500. The unique combination of our sophisticated global payments platform and white glove service has successfully helped customers gain more control, increase visibility, and experience significant efficiencies for the line of business, Finance, AP and their suppliers. We planted our first seeds in the travel and meetings space providing robust solutions for large companies to get their suppliers paid while keeping control and increasing the visibility of their spend. As Covid 19 ravaged the travel and meeting industry and companies focused on going digital, Eved has expanded to include Media and Entertainment, focused on Film & TV Productions and Music Recording Labels. We believe that employees need to focus on what they do best, deliver on their business objectives. They should not be spending their time on processes that software can automate. Therefore, we developed a digital, centralized payment solution that meets the needs of the most robust companies in the world. Our easy to use interface coupled with our global payments engine makes getting suppliers paid easy and secure. A solution that Procurement, Finance, and The Business can all get behind, because it helps all stakeholders move from manual to digital.

Marina Biotech’s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103

FemmePharma is dedicated to women’s menopausal health (natural and chemical). Created by women and backed by science, we are committed to finding a way to address women’s health issues and providing access to women directly without the need for a prescription. Our mission is to bring innovative products to market that not only safely and effectively alleviate the symptoms of menopause, but also meet women where they are. FemmePharma's pharmaceutical-grade research and development process, strict product manufacturing standards, and white-glove customer service provide women with the symptomatic relief and peace of mind that they have been seeking. From concept to formulation, from design to delivery, every product is created for women by women. Instagram: https://www.instagram.com/femmepharma Facebook: https://www.facebook.com/FemmePharma Twitter: https://twitter.com/FemmePharma

Eved is your global payment partner for Events, Media, and Entertainment. We automate and centralize the processing of invoices and payments with a single workflow: providing security, efficiency, and visibility. Over the last 5 years, Eved has delighted the most sophisticated global companies in the Fortune 500. The unique combination of our sophisticated global payments platform and white glove service has successfully helped customers gain more control, increase visibility, and experience significant efficiencies for the line of business, Finance, AP and their suppliers. We planted our first seeds in the travel and meetings space providing robust solutions for large companies to get their suppliers paid while keeping control and increasing the visibility of their spend. As Covid 19 ravaged the travel and meeting industry and companies focused on going digital, Eved has expanded to include Media and Entertainment, focused on Film & TV Productions and Music Recording Labels. We believe that employees need to focus on what they do best, deliver on their business objectives. They should not be spending their time on processes that software can automate. Therefore, we developed a digital, centralized payment solution that meets the needs of the most robust companies in the world. Our easy to use interface coupled with our global payments engine makes getting suppliers paid easy and secure. A solution that Procurement, Finance, and The Business can all get behind, because it helps all stakeholders move from manual to digital.

Marina Biotech’s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103

FemmePharma is dedicated to women’s menopausal health (natural and chemical). Created by women and backed by science, we are committed to finding a way to address women’s health issues and providing access to women directly without the need for a prescription. Our mission is to bring innovative products to market that not only safely and effectively alleviate the symptoms of menopause, but also meet women where they are. FemmePharma's pharmaceutical-grade research and development process, strict product manufacturing standards, and white-glove customer service provide women with the symptomatic relief and peace of mind that they have been seeking. From concept to formulation, from design to delivery, every product is created for women by women. Instagram: https://www.instagram.com/femmepharma Facebook: https://www.facebook.com/FemmePharma Twitter: https://twitter.com/FemmePharma

Outcome Health and PatientPoint have combined to create a new company, PatientPoint Health Technologies™. Read more: https://bit.ly/3qDHhuF PatientPoint® is the trusted partner for tech-enabled patient engagement solutions that enhance the patient experience across the entire care journey. Our solutions create more effective doctor-patient interactions and deliver high value for patients, providers and healthcare sponsors. Through our 150k unique healthcare provider relationships, PatientPoint’s solutions impact roughly 750 million patient visits each year, further advancing our mission of making every doctor-patient engagement better®.